Advancing lung cancer therapy – leveraging cell biology to improve immunotherapy and anti-angiogenic strategies
Journal of Cell Science · 01.03.2026 · 139 (5)
DOI: 10.1242/jcs.264224 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Cell Science, online erschienen am 10.03.2026. Verfasst von Jozafina Haj-Shomaly und 4 weiteren Autor:innen. Beteiligte Einrichtung: Adhesion and Angiogenesis Lab, Centre for Tumour Microenvironment, John Vane Science Centre, Barts Cancer Institute, Charterhouse Square, Queen Mary …. Hauptthemen laut MEDLINE: Immunotherapy, Lung Neoplasms, Angiogenesis Inhibitors, Neovascularization, Pathologic. Die Arbeit nennt 151 Literaturangaben. Gefördert von: Pancreatic Cancer Research Fund, Vatat scholarship, Weizmann Institute of Science.
Abstract (Originalsprache)
The standard of care for lung cancer typically involves a multidisciplinary approach including surgery, chemotherapy, radiotherapy, targeted therapy and immunotherapy, with treatment strategies tailored to the cancer subtype, disease stage and patient condition. Despite these efforts, the overall 5-year relative survival rate remains low, at ∼27%, with outcomes varying significantly by stage at diagnosis. These limited survival rates highlight the urgent need for more effective therapeutic strategies and innovative treatment approaches. A combination therapy involving immune checkpoint inhibitors and anti-angiogenic drugs has emerged as a promising strategy for lung cancer treatment. However, challenges such as low response rates and acquired resistance continue to hinder the success of this approach. The tumour microenvironment, particularly the intricate molecular and cellular interactions between immune cells and endothelial cells, plays a pivotal role in determining the efficacy of and resistance to therapeutic strategies. In this Perspective, we discuss the interplay between cancer cells and immune and vascular cells, highlighting how a detailed understanding of the cell biology of the tumour microenvironment might advance current therapies. Additionally, we describe alternative vascular modulation approaches that could potentially improve the effectiveness of immune checkpoint inhibitors in lung cancer treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Adhesion and Angiogenesis Lab, Centre for Tumour Microenvironment, John Vane Science Centre, Barts Cancer Institute, Charterhouse Square, Queen Mary University of London, London EC1M 6BQ, UK.
ORCID-Profile: Kairbaan M Hodivala-Dilke, Gabriela D'Amico
Förderung
- Pancreatic Cancer Research Fund
- Vatat scholarship
- Weizmann Institute of Science
- Barts Charity
- HEFCE
- Queen Mary University of London
- Medical Research Council
- Worldwide Cancer Research
Zitieren
APA
Haj-Shomaly, J., Castillo-Kauil, A., Bloom, C., Hodivala-Dilke, K. M., & D'Amico, G. (2026). Advancing lung cancer therapy – leveraging cell biology to improve immunotherapy and anti-angiogenic strategies. Journal of Cell Science, 139(5). https://doi.org/10.1242/jcs.264224
Vancouver
Haj-Shomaly J, Castillo-Kauil A, Bloom C, Hodivala-Dilke KM, D'Amico G. Advancing lung cancer therapy – leveraging cell biology to improve immunotherapy and anti-angiogenic strategies. Journal of Cell Science. 2026;139(5). doi:10.1242/jcs.264224
BibTeX
@article{HajShomaly2026,
author = {Haj-Shomaly, Jozafina and Castillo-Kauil, Alejandro and Bloom, Carla and Hodivala-Dilke, Kairbaan M and D'Amico, Gabriela},
title = {Advancing lung cancer therapy – leveraging cell biology to improve immunotherapy and anti-angiogenic strategies},
journal = {Journal of Cell Science},
year = {2026},
volume = {139},
number = {5},
doi = {10.1242/jcs.264224}
}
EUVIMED